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Magainin-2 (MAG2) is a polycationic antimicrobial peptide isolated from the skin of the
African clawed frog Xenopus laevis. It has a wide spectrum of antimicrobial activities
against gram-positive and gram-negative bacteria, fungi, and induces osmotic lysis of proto-
zoa. MAG2 also possesses antiviral and antitumoral properties. These activities make this
peptide a promising candidate for therapeutic applications. Recombinant expression systems
are necessary for the affordable production of large amounts of the biologically active pep-
tide. In this work, MAG2 has been cloned to the N-terminal of a family III carbohydrate-
binding module fused to the linker sequence (LK-CBM3) from Clostridium thermocellum;
a formic acid recognition site was introduced between the two modules for chemical cleavage
of the peptide. The recombinant protein MAG2-LK-CBM3 was expressed in Escherichia coli
BL21 (DE3) and MAG2 was successfully cleaved and purified from the fusion partner
LK-CBM3. Its functionality was confirmed by testing its activity against gram-negative bacteria.
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Introduction
Bacterial resistance to antibiotics, first noticed back in the
1950s, is a growing concern for public health.1 Because of
their mechanism of action, the antimicrobial peptides (AMPs)
represent an attractive alternative as human therapeutics.
AMPs are part of the innate immune system and represent an
important component of immune defense. They have a large
spectrum of antimicrobial activities against gram-positive and
gram-negative bacteria, fungi,2 and viruses like influenza A3
or human immunodeficiency virus (HIV-1).4 Moreover,
certain peptides may possess anticancer activity.5 AMPs are
generally defined as cationic, amphipathic peptides, with less
than 50 amino acids, including multiple arginine and lysine
residues6 and show inhibitory concentrations (MIC) as low as
0.25–4 lg/ml.7 They are widely distributed in nature, from
insects to plants and animal species; at least 1972 AMPs have
been identified so far (http://aps.unmc.edu/AP/main.php; May
2012).
Magainins are AMPs isolated from the skin of the African
clawed frog Xenopus laevis.8,9 Magainins are comprised of
21–27 amino acid residues that create an a-helical secondary
structure characterized by separate cationic and hydrophobic
faces.5 Magainin-2 (GIGKFLHSAKKFGKAFVGEIMNS), a
polycationic peptide with a net positive charge of 3, has
been well studied for its killing action on various microor-
ganisms, as well as on tumor cells.10–12 It acts by permeabi-
lizing their membranes, either in a detergent-like manner or
by making well-structured channels.13,14 Magainin-2 and its
more potent synthetic analogs (magainins A, B, and G) cause
the rapid lysis of both hematopoietic and solid tumor cell
lines at concentrations 5- to 10-fold lower than those lytic for
normal human peripheral blood lymphocytes or neutrophils.5
Many bacterial and fungal enzymes that hydrolyze insolu-
ble carbohydrates share a common structure composed of a
catalytic domain linked to a carbohydrate-binding module
(CBM). CBMs that are specific for insoluble cellulose (cellu-
lose binding domain–CBD) represent the predominant cate-
gory. The CBMs can be grouped into distinctive families on
the basis of amino acid sequence similarities15; 64 families
of CBMs have been recognized so far (http://www.cazy.org/
fam/acc_CBM.html; May 2012).
Family-III CBDs normally comprise 150 amino acids
residues, have been identified in many different bacterial
enzymes, and also in nonhydrolytic proteins.16 Clostridium
thermocellum produces a multienzyme complex of cellulases
and hemicellulases, termed the cellulosome, which is
assembled by the scaffoldin protein CipA. Binding of the
cellulosome to the plant cell wall is driven by the action of
the CipA family 3 CBM (CBM3), which presents high affin-
ity for crystalline cellulose.17 CBM3 belongs to the all-b
family of proteins and is arranged in two antiparallel b
sheets that form a b sandwich with jellyroll topology.16
AMPs have potential to provide an important break-
through and form the basis for a new class of antibiotics.
Since, AMPs are usually short peptides, chemical synthesis
could be one approach for producing them. However, a cost-
effective and scalable method of active production is
required in order to commercialize the bacterial peptides.
Bacterial expression of heterologs proteins is an easy and
inexpensive tool for producing large amounts of recombinant
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proteins.18 Production of recombinant expression of AMPs in
Escherichia coli is potentially limited because of their toxic-
ity to host cells and susceptibility to proteolytic degradation,
which can be avoided using fusion protein approach.19 There
are several fusion partners (e.g., solubility-enhancing, aggre-
gation-promoting, and self-cleavable carriers, etc), cleavage
methods and optimization options for AMPs production in E.
coli.20 However, the very few works describing MAG2
expression in E. coli, including using fusing partners,21 may
indicate that it is very difficult to produce MAG2 in bacteria.
As Magainin displays high antibacterial and antitumor activ-
ities,11,12 the development of a method to obtain recombinant
and functional Magainin but at low cost is crucial for its
expansion as a therapeutic agent.18,19 Moreover, potent ana-
logs of MAG2 have been obtained by substitutions of gly-
cine or serine with alanine residues and amidation of the
C-terminus, which resulted in enhanced a-helical structure
and antimicrobial activity. Studies with pronase digestion
suggested that the lower antimicrobial of MAG2 activity,
when comparing to analogs, may be due to higher suscepti-
bility to proteolysis in the presence of membranes.10 In this
work, the fusion of MAG2 with the CBM3 was attempted as
an approach for its large scale production and could also be
used for the production of Magainin analogs.
Materials and Methods
Construction of expression vectors
The gene encoding CBM3 fused to the endogenous CipA
N-terminal linker sequence (LK) has previously been cloned
in the expression vector pET-21a (Novagen), in our labora-
tory.17 The expression vector was constructed with MAG2 at
the N-terminal (MAG2-LK-CBM3) of the pET-21a vector
(Figure 1). This vector was constructed to allow the cloning
of MAG2 at the N-terminal of the LK-CBM3 while keeping
a C-terminal His 6-tag.
The nucleotide sequence of MAG2 was engineered to
allow codon optimization in E. coli. The sequence encoding
the peptide was included in the primers in fusion with the
gene of a family 3 CBM. The pET-21a-LK-CBM3 was used
as template. For the MAG2-LK-CBM3 construction, the fol-
lowing primers were used: 50-GGA ATTC CAT ATG GGT
ATT GGT AAA TTT CTG CAT AGC GCG AAA AAA
TTT GGT AAA GCG TTT GTG GGT GAA ATT ATG
AAC AGC GAT CCG ACA CCG ACC AAG GGA GCA-30
(forward primer) and 50-CAC CTC GAG TTC TTT ACC
CCA TAC AAG AAC-30 (reverse primer). NdeI, XhoI
(MAG2-LK-CBM3) recognition sites are shown in bold. In
order to allow the chemical cleavage with formic acid, pro-
line and aspartate residues were introduced (underlined).
PCR reactions were performed using the DNA polymerase
VENT (Stratagene). The PCR reactions were performed as
follows: preheating at 95C for 2 min, 30 cycles at 95C for
30 s, 30 s at 52C, and 30 s at 72C, followed by a final
elongation stage at 72C for 10 min. The amplified product
was recovered from 1% agarose gel, digested with NdeI and
XhoI and ligated into pET-21a plasmids. The plasmid was
sequenced to ensure that no mutations had occurred during
PCR. Figure 1 represents MAG2-LK-CBM3 construction.
Expression and purification of fusion protein
The recombinant plasmid pET-21a-MAG2-LK-CBM3 was
transformed into the E. coli strain BL21 (DE3) (Novagen)
for protein expression. The bacterial strain was grown in
Luria–Bertani broth (LB) containing 100 lg/ml of ampicil-
lin, at 37C, to mid-exponential phase (OD595 0.6). Expres-
sion of the fusion protein was initiated by adding isopropyl-
b-D-thiogalactopyranoside (IPTG) at a final concentration of
1 mM and the culture was incubated overnight at 37C.
Then, the cells were centrifuged at 6000 rpm for 15 min at
4C, resuspended in 150 mM Tris–HCl, pH 7.0, 20 mM NaCl,
5 mM CaCl2(2H2O) buffer (CBM buffer) and sonicated in ice
for 6 min. The cells were centrifuged at 12,000 rpm, for 30
min at 4C and the soluble fraction was collected.
The His 6-tagged recombinant protein was purified by im-
mobilized metal ion affinity chromatography (IMAC), using
5 ml Niquel His-Trap Columns (GE Health). The column
charged with 0.1 M NiSO4 was equilibrated with 20 mM of
Na3PO4, 500 mM NaCl, 40 mM Imidazole, pH 7.4. The cell
extract was loaded into the column, which was washed with
the equilibration buffer. Finally, the recombinant protein were
eluted with 20 mM Na3PO4, 500 mM NaCl, 300 mM Imidaz-
ole, pH 7.4. After purification, protein buffer was exchanged
into CBM buffer, using PD10-columns (GE Health).
The recombinant protein was also purified on cellulose
CF11 (Sigma), exploiting the CBM3 cellulose-binding prop-
erties, as follows: 20 ml of cell-free extracts were mixed
with 2 g of cellulose and incubated, with agitation, for 1 h at
4C. The cellulose with bound proteins was then centrifuged
and washed 5 times with CBM buffer.
Formic acid cleavage and MAG2 purification
To cleave MAG2 of the recombinant protein, a 50% for-
mic acid solution (20 ml of distilled water and 26 ml 88%
formic acid) was applied directly to cellulose with the
adsorbed fusion protein. In the case of proteins purified by
IMAC, formic acid was mixed with the purified protein (20
ml of pure protein and 26 ml of formic acid 88%). The mix-
ture was then incubated for 24 h, at 50C. The supernatant
was separated after centrifugation at 12,000 rpm, for 30 min,
and lyophilized to remove formic acid. The cleavage was
confirmed by SDS-PAGE using a 16.5% Tris-Tricine gel.
The purification of MAG2 was achieved by reverse-phase
HPLC, using an YMC C18 preparative column (250  30 mm)
equilibrated with aqueous acetonitrile (5%)/0.1% trifluoracetic
acid (TFA). The peptide was eluted using a linear gradient of
acetonitrile from 5% to 90% at a flow rate of 5 ml/min. The elu-
tion was monitored at 215 nm. Several peaks were collected and
analyzed by SDS–PAGE using a 16% Tris-Tricine gel. The frac-
tion corresponding to pure MAG2 was lyophilized.
The purification of MAG2 was also attempted through ultra-
filtration in a Centricon with 5 kDa molecular weight cut-off
(Millipore). The filtrate was collected and analyzed by 16%
Tris-Tricine gel SDS–PAGE. The concentration of the
recombinant peptide was quantified using Waddell’s method.22
Figure 1. Schematic representation of MAG2-LK-CBM3
construction.
The AspPro site for chemical cleavage with formic acid is
shown in black; H: His-tag.
18 Biotechnol. Prog., 2013, Vol. 29, No. 1
MALDI-TOF mass spectrometry
The formic acid cleavage of the recombinant proteins and
the purity of MAG2 were evaluated by mass spectrometry at
the Institute of Molecular Pathology and Immunology of the
University of Porto (IPATIMUP). Sample was desalted and
concentrated using microC18 ZipTips (Millipore, USA)
accordingly to the manufacturer’s protocol. The sample was
eluted with the matrix a-cyano-4-hydroxycinnamic acid (5 mg/
ml) in 50% acetonitrile/0.1% TFA and spotted onto a stainless
steel 192-well MALDI plate. After sample crystallization,
mass spectrum acquisition was performed using a 4700 Proteo-
mics Analyzer MALDI-TOF/TOF (Applied Biosystems,
USA). Mass spectra were acquired in positive linear mode for
1–15 kDa (m/z) mass window and in positive reflector mode
for the ranges 700–7000, 4000–5000, and 4585–4600 Da
(m/z). External calibration of the mass spectrum was performed
using Applied Biosystems Calibration Mix 3 standards.
Antibacterial activity
The antibacterial activity of the pure peptide was quanti-
fied in 96-well polypropylene microtiter plates, as described
by Vogt et al.,23 with some modifications. E. coli strain K12
was grown at 37C in LB medium until mid-logarithmic
phase (OD600 0.5). The cells were then resuspended in LB at
2  107 and 2  106 cells/ml; 100 ll of peptides, at different
concentrations, were inoculated with 100 ll of bacterial sus-
pension, incubated overnight at 37C and the bacterial growth
was assessed by the measurement of optical density at
620 nm. Each assay was repeated three times, using as refer-
ence sterile deionized water instead of the peptide solutions.
Results and Discussion
Expression and purification of recombinant protein
The antimicrobial peptide MAG2 was successfully cloned
at the N-terminal of the LK-CBM3 in the expression vector
pET-21a. After transformation of the recombinant plasmid
into E. coli BL21 (DE3), several fermentation conditions,
including induction temperature (18, 25, 30, and 37C),
IPTG concentration (0.1, 0.5, and 1 mM), induction time (4
h and overnight), OD595 nm at the induction (0.4 and 0.6)
were tested, attempting to optimize the production of the
recombinant protein in the soluble form. The fusion protein
MAG2-LK-CBM3 (24 kDa) was successfully expressed in
soluble form after induction at 37C with 1 mM IPTG (Fig-
ure 2). Two bands that may correspond to the expressed pro-
teins after induction were observed, either in soluble and
insoluble fractions; however, according to the purification
results (Figure 3), the recombinant MAG2-LK-CBM3 corre-
sponds to the band with higher molecular weight (indicated
with an arrow in Figure 2), therefore only a small amount of
fusion protein was expressed under insoluble form.
There are two major problems in the expression of AMPs
in E. coli: the cytoxicity of the peptides to the host and the
sensitivity of peptides with positively charged amino acids to
proteases. A common strategy for the production of recombi-
nant peptides involves genetic attachment to a well
expressed protein to generate a fusion protein. The protein
acts to protect the peptide from proteolytic digestion and can
protect the host from potential toxicity associated with some
peptides. The high toxicity of the peptides usually leads to
expression in inclusions bodies or in aggregate form. To
overcome this situation, the use of a fusion partner is highly
recommended. There are a number of fusion partner proteins
available that differ in size and properties; some facilitate
soluble expression while others promote the formation of
inclusion bodies.24–26 Guerreiro et al.17 reported the soluble
expression of the family 3 CBM from C. thermocellum—
also used in this work—fused to three different AMPs:
LKLLKKL, LKKLLKKLKKLLKK, and porcine myeloid
antibacterial peptide-23 (PMAP-23) RIIDLLWRVRRPQKPK
FVTVWVR. Only the protein LKLLKKLLKLLKKLGG
GK-LK-CBM3 was found to be insoluble when expressed by
different E. coli strains, under a range of induction conditions.
Also, the constructs with CBM fused to the human cathalicidin
LL37 have been previously successfully expressed in our
group.27,28 Therefore, although the solubility of AMPs fused to
the CBM3 is rather unpredictable, the expression of the fusion
proteins was, in all cases, successful. In this work, the expres-
sion of soluble magainin-2, fused at the N-terminus of
LK-CBM3, was achieved. The family 3 cellulose-binding
module was chosen as fusion partner considering the
previously demonstrated successful overexpression of several
CBM-AMPs, the simplicity of purification using cellulose as
an affinity chromatography matrix, and also the low cost of
cellulose, which makes this an attractive purification matrix,
therefore we explored the recovery of the MAG2-LK-CBM3
using cellulose CF11 fibers.
Figure 2. Expression of recombinant protein MAG2-LK-CBM3.
Mw, protein molecular weight marker; (1) before induction; (2)
insoluble fraction; and (3) soluble fraction.
Figure 3. A: Purification of MAG2-LK-CBM3 on cellulose
fibers.
Mw, protein molecular weight marker; (1) total fraction; (2)
unbound protein; (3) first cellulose wash; (4) fifth cellulose
wash; (5) bound protein eluted with 1% SDS. B: Purification
of LK-CBM3-MAG2 by IMAC. Mw, protein molecular weight
marker; (1) uninduced cells; (2) insoluble fraction; (3) soluble
fraction; (4) column filtrate; (5 and 6) column washes; 7, pure
protein.
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As demonstrated by Tomme et al., CBM3 binds cellulose
with high affinity. In fact, the equilibrium affinity constant
(Ka) for Avicel was reported to be 7.7  106 M1.29 Figure
3 shows that the fusion of the peptide MAG2 did not affect
the binding to cellulose. However, unlike the recombinant
protein described in the works listed above, in the case of
MAG2-LK-CBM the purification of on cellulose was not
fully effective due to unspecific binding of contaminating
proteins, and we therefore explored purification using IMAC
system by exploiting the histidine tag. This allowed the
more efficient recovery of purified fusion protein as shown
in Figure 3.
Chemical cleavage of MAG2-LK-CBM3
Formic acid was chosen for hydrolysis instead of thrombin
or factor Xa proteases, to reduce production costs. After purifi-
cation with cellulose, 50% formic acid was applied to cleave
the AMP MAG2 from the fusion carrier, CBM3. The formic
acid cleavage of MAG2 (2.5 kDa) from the fusion partner
LK-CBM3 was successful, as illustrated in Figure 4. After hy-
drolysis, the mixture was lyophilized to remove the formic
acid. The protein was resuspended in ultrapure water and cen-
trifuged to remove proteins degraded by the formic acid.
Figure 4 shows that a significant number of contaminants
were present in the supernatant after the formic acid cleav-
age. Consequently, the supernatant containing the MAG2
peptide was purified by reverse-phase HPLC. The fractions
corresponding to the major peaks (Figure 5A) were collected
and the purity of the peptide was checked on 16.5% Tris–
Tricine gel (Figure 5B).
Figure 4. Formic acid cleavage of the recombinant protein
MAG2-LK-CBM3.
Mw, protein molecular weight marker; insoluble fraction of
cleaved MAG2-LK-CBM3; 2, supernatant of cleaved MAG2-
LK-CBM3.
Figure 5. Reverse-phase HPLC chromatogram of MAG2-LK-CBM3 (A). RP-HPLC peak fractions (B).
Mw, protein molecular weight marker; lanes 1–8, peak fractions of cleaved MAG2-LK-CBM3.
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The fraction with a retention time of about 50 min (peak 7)
contained the mostly pure antimicrobial peptide MAG2. Some
contaminant proteins were not efficiently removed by
RP-HPLC and remained present in low amounts. To confirm
the purity and molecular weight of the peptide, MALDI-TOF
analysis was performed (Figure 6).
The peptide resulting from the hydrolysis has 24 amino acids
with a C-terminal aspartic acid (MAG2-D), left by the chemical
cleavage and a theoretical molecular weight of 2582 Da. The
MALDI-TOF analysis confirmed the molecular weight of the
recombinant peptide as well as its purity. This molecular weight
indicates that the N-terminal methionine from the translation
process has been cleaved. Giglione et al.30 reported that 55–
70% of mature proteins are subjected to N-terminal Met exci-
sion and this was the case with MAG2-LK-CBM3.
Antibacterial Activity of MAG2-LK-CBM3
After the successful expression and purification of MAG2, its
activity was tested against E. coli K12, using different protein
concentration between 62.5 and 200 lg/ml, in order to deter-
mine the MIC of recombinant MAG2. The concentration of the
peptide was quantified by UV spectroscopy using the Waddell’s
method.22 Figure 7 demonstrates that MAG2 has antimicrobial
activity, with a MIC of about 100 lg/ml (39 lM), a value sim-
ilar to the ones found in the in the literature. 31–33 At lower con-
centration, MAG2 inhibited bacterial growth only partially, an
effect dependent on the initial cellular density. The fusion pro-
tein MAG2-CBM3 did not show antimicrobial activity (results
not shown).
The results suggest that the negatively charged C-terminal as-
partic acid, left from acid cleavage, does not affect the antibac-
terial activity of the recombinant protein. Since, AMPs interact
by electrostatic forces with the negatively charged bacterial
membrane phospholipids, eventually leading to its disruption,34
the lower net charge of the produced MAG2 (þ2) could affect
is antibacterial activity, but actually this was not the case.
To date, the successful cloning, expression, and purification
of the AMP Magainin-2 in bacteria has not been reported. Bar-
rell et al. reported the successful expression of MAG2 fused to
the well-known thioredox into raise antibodies.21 However, they
did not cleave and purify MAG2 from its expression partner. A
Magainin analogs (MSI-344) was expressed and purified with
good yields from E. coli inclusion bodies. The recombinant pep-
tide kept its antibacterial activity.35,36 In a different approach,
Fan and Li successfully expressed MAG2 in a mammalian cell
system at high productivity and efficiency.37 The very few
works reported may indicate that it is very difficult to produce
MAG2 in bacteria. Here we presented a strategy to produce
active MAG2, which could be used to produce MAG2 analogs
or other AMPs. One challenge with this approach is determining
efficient elution conditions that do not result in contaminant pro-
teins during purification using CF11 cellulose fibers. Improve-
ments in peptide recovery might be achieved by combining
cellulose affinity with on column cleavage followed by immobi-
lized metal affinity chromatography to remove contaminants.
Conclusions
Some AMPs can physically attack the microbial mem-
branes to kill microbes, even those that present antibiotic-
Figure 6. MALDI-TOF MS analysis of purified MAG2.
The measured molecular weight is very close to the predicted theoretical value (2582 Da).
Figure 7. Antibacterial activity of MAG2 against E. coli K12.
Bacterial growth was inhibited at a concentration of 100 lg/ml
(39 lM) of recombinant MAG2 to an initial cell concentration
of 1x106 (black gray) or 1x105 (light gray). Results are repre-
sented as mean SD of OD600 nm.
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resistant mechanisms. These peptides have been the focus of
increasing interest, arising as excellent candidates for new
types of antibiotics. Production of peptide antibiotics at a
large scale is a significant challenge for developing commer-
cial products. Expression of recombinant AMPs is not always
successful, either because of their activity to the host and/or
proteolysis of the recombinant peptides during synthesis. In
this work, the peptide MAG2 was successfully expressed,
cleaved and purified. The isolated peptide bears antibacterial
activity. The CBM3 utilization as fusion partner appears to
be very effective for production and purification of AMPs.
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